Table 1.
Demographic, clinical, and cognitive data of the patients and controls.
| Mean (±SD) | Patients (N = 12) | Controls (N = 12) |
|---|---|---|
| Age | 41 ± 10 | 39 ± 12 |
| Male: Female | 8: 4 | 6: 6 |
| Years of Education | 15 ± 3 | 15 ± 2 |
| PANSS | ||
| Positive | 11.3 ± 3.0 | — |
| Negative | 11.7 ± 3.4 | — |
| General | 23.6 ± 2.8 | — |
| Total | 50.1 ± 6.2 | — |
| WTAR FS IQ | 106 ± 10 | — |
| Letter-Number-Span | 12 ± 3 | — |
| HVLT | — | |
| Retention (%) | 83.4 ± 14.8 | — |
| Discrimination Index | 10.5 ± 1.4 | — |
| TMT (seconds) | — | |
| A | 30.6 ± 9.7 | — |
| B | 71.7 ± 36.5 | — |
| CPZ Equivalent Doses (mg/day) | 330 ± 287 | — |
SD: standard deviation, PANSS: positive and negative symptom scale, WTAR FS IQ: Wechsler Test of Adult Reading Full Scale Intelligence Quotient, HVLT: Hopkins Verbal Learning Test, TMT: Trail Making Test, CPZ: chlorpromazine.